Pharmaceutical composition containing atorvastatin calcium and preparation method of pharmaceutical composition

A technology of atorvastatin calcium and composition, applied in the field of pharmaceutical composition containing atorvastatin calcium and its preparation, capable of solving problems such as poor solubility of atorvastatin calcium

Inactive Publication Date: 2021-01-26
HUNAN DINUO PHARMA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The technical problem to be solved in the present invention is to overcome the poor solubility of atorvastatin calcium in the prior art and the defects of selecting hydroxypropyl cellulose as the binder, and provide a pharmaceutical composition containing atorvastatin calcium and its preparation method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing atorvastatin calcium and preparation method of pharmaceutical composition
  • Pharmaceutical composition containing atorvastatin calcium and preparation method of pharmaceutical composition
  • Pharmaceutical composition containing atorvastatin calcium and preparation method of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The pharmaceutical composition containing atorvastatin calcium of the present embodiment mainly includes the following raw materials in parts by weight:

[0032] 9.5-11 parts by weight of atorvastatin calcium, 28-32 parts by weight of calcium carbonate, 34-38 parts by weight of microcrystalline cellulose, 55-65 parts by weight of lactose, 7-8 parts by weight of croscarmellose sodium, 0.4-0.6 parts by weight of polysorbate 80, 1.1-1.2 parts by weight of magnesium stearate, and 4-5 parts by weight of povidone K30.

[0033] Further, the raw materials of the following parts by weight are preferred: 10.33 parts by weight of atorvastatin calcium, 30 parts by weight of calcium carbonate, 36 parts by weight of microcrystalline cellulose, 60 parts by weight of lactose, 7.5 parts by weight of croscarmellose sodium, poly 0.5 parts by weight of sorbate 80, 1.16 parts by weight of magnesium stearate, and 4.5 parts by weight of povidone K30.

[0034] Further, povidone K30 is added i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a pharmaceutical composition containing atorvastatin calcium and a preparation method of the pharmaceutical composition. The pharmaceutical composition containing atorvastatin calcium is mainly prepared from the following raw materials in parts by weight: 9.5-11 parts of atorvastatin calcium, 28-32 parts of calcium carbonate, 34-38 parts of microcrystalline cellulose, 55-65 parts of lactose, 7-8 parts of croscarmellose sodium, 0.4-0.6 part of polysorbate 80, 1.1-1.2 parts of magnesium stearate and 4-5 parts of povidone K30. The povidone K30 is selected to replace hydroxy propyl cellulose. After oral administration, the povidone is not absorbed by gastrointestinal tracts and mucous membranes and non-toxic. In addition, the povidone is non-irritant to the skinand free of allergic reaction. Absorption and utilization of active ingredients are not influenced, and adverse reactions with other auxiliary materials are also avoided.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a pharmaceutical composition containing atorvastatin calcium and a preparation method thereof. Background technique [0002] Atorvastatin calcium, chemical name: (3R,5R) 7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(anicarbamoyl) )-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate calcium trihydrate is a 3-hydroxy-3-methylglutaryl coenzyme A HMG-CoA reductase inhibitor, its main role is Lower plasma low-density lipoprotein cholesterol (LDL-C) levels. Due to the characteristics of small adverse reactions, disappearing after drug withdrawal and strong lipid-lowering effect, it is widely used in the treatment of hyperlipidemia, especially hypercholesterolemia. [0003] Atorvastatin calcium tablets were developed by Warner-Limbert Company of the United States and were launched in 1996. They were then produced by Dalian Pfizer in China under the trade nam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/36A61K47/32A61K47/02A61K31/40A61P3/06
CPCA61K9/2866A61K9/2027A61K9/2009A61K31/40A61P3/06
Inventor 易志恒潘琳丁小军李甜
Owner HUNAN DINUO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap